According to a recent LinkedIn post from ABM Respiratory Care, the company engaged with attendees at the ATS conference, emphasizing discussions around airway clearance, clinical practice, and potential research collaboration. The post highlights interest from clinicians and researchers in its BiWaze® Cough and BiWaze® Clear technologies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post suggests that ABM Respiratory Care is positioning its BiWaze platform as a differentiated solution in respiratory care, particularly in airway clearance. For investors, this level of professional engagement and focus on research collaboration may indicate efforts to build clinical validation, expand adoption in care settings, and support longer-term revenue growth in the respiratory device market.
As shared in the post, ABM Respiratory Care is also directing non-attendees to schedule product demos, indicating an ongoing commercial push beyond the conference. This approach could help extend the impact of event-driven visibility, potentially strengthening its sales pipeline and reinforcing its competitive position among specialized respiratory therapy and airway clearance providers.